Do drug transporter (ABCB1) SNPs and P-glycoprotein function influence cyclosporine and macrolides exposure in renal transplant patients? Results of the pharmacogenomic substudy within the symphony study

Transplant International

Volumn 26, Issue 2, 2013, Pages 177-186

  Llaudõ, Inés ^a   Colom, Helena ^b   Giménez Bonafé, Pepita ^b   Torras, Joan ^a   Caldés, Anna ^a   Sarrias, Maria ^a   Cruzado, Josep Mâ ^a   Oppenheimer, Federico ^c   Sánchez Plumed, Jaime ^d   Gentil, Miguel Ángel ^e   Ekberg, Henrik ^f   Grinyõ, Josep Mâ ^a   Lloberas, Núria ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

^d HOSPITAL UNIVERSITARIO LA FE   (Spain)

^e HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^f University Hospital   (Sweden)

Author keywords

ABCB1; cyclosporine; macrolides; P glycoprotein; polymorphisms; transplantation

Indexed keywords

ALBUMIN; CREATININE; CYCLOSPORIN; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; MYCOPHENOLIC ACID; RAPAMYCIN; RHODAMINE 123; STEROID; TACROLIMUS;

ADULT; AREA UNDER THE CURVE; ARTICLE; CD3+ T LYMPHOCYTE; CONTROLLED STUDY; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; ANTIGENS, CD3; CYCLOSPORINE; FEMALE; FLOW CYTOMETRY; GENOTYPE; HAPLOTYPES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LEUKOCYTES, MONONUCLEAR; MACROLIDES; MALE; MIDDLE AGED; P-GLYCOPROTEIN; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; STEROIDS;

EID: 84872543515     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/tri.12018     Document Type: Article

References (59)

1. Fromm MF,. Importance of P-glycoprotein at blood-tissue barriers. Trends Pharmacol Sci 2004: 25: 423.
2. Evans WE, McLeod HL,. Pharmacogenomics-drug disposition, drug targets, and side effects. N Engl J Med 2003: 348: 538.
3. Ambudkar SV, Kim IW, Sauna ZE,. The power of the pump: mechanisms of action of P-glycoprotein (ABCB1). Eur J Pharm Sci 2006: 27: 392.
4. Callaghan R, Crowley E, Potter S, Kerr ID,. P-glycoprotein: so many ways to turn it on. J Clin Pharmacol 2008: 48: 365.
5. Bebawy M, Sze DM,. Targeting P-glycoprotein for effective oral anti-cancer chemotherapeutics. Curr Cancer Drug Targets 2008: 8: 47.
6. Li X, Li JP, Yuan HY, et al,. Recent advances in P-glycoprotein-mediated multidrug resistance reversal mechanisms. Methods Find Exp Clin Pharmacol 2007: 29: 607.
7. Calado RT, Falcao RP, Garcia AB, Gabellini SM, Zago MA, Franco RF,. Influence of functional MDR1 gene polymorphisms on P-glycoprotein activity in CD34+ hematopoietic stem cells. Haematologica 2002: 87: 564.
8. Pendse SS, Behjati S, Schatton T, Izawa A, Sayegh MH, Frank MH,. P-glycoprotein functions as a differentiation switch in antigen presenting cell maturation. Am J Transplant 2006: 6: 2884.
9. van de Ven R, de Jong MC, Reurs AW, et al,. Dendritic cells require multidrug resistance protein 1 (ABCC1) transporter activity for differentiation. J Immunol 2006: 176: 5191.
10. Frank MH, Denton MD, Alexander SI, Khoury SJ, Sayegh MH, Briscoe DM,. Specific MDR1 P-glycoprotein blockade inhibits human alloimmune T cell activation in vitro. J Immunol 2001: 166: 2451.
11. Sun J, He ZG, Cheng G, Wang SJ, Hao XH, Zou MJ,. Multidrug resistance P-glycoprotein: crucial significance in drug disposition and interaction. Med Sci Monit. 2004; 10: RA5.
12. Sharom FJ,. ABC multidrug transporters: structure, function and role in chemoresistance. Pharmacogenomics 2008: 9: 105.
13. Hoffmeyer S, Burk O, von Richter O, et al,. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000: 97: 3473.
14. Choudhuri S, Klaassen CD,. Structure, function, expression, genomic organization, and single nucleotide polymorphisms of human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP) efflux transporters. Int J Toxicol 2006: 25: 231.
15. Kroetz DL, Pauli-Magnus C, Hodges LM, et al,. Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene. Pharmacogenetics 2003: 13: 481.
16. Pauli-Magnus C, Kroetz DL,. Functional implications of genetic polymorphisms in the multidrug resistance gene MDR1 (ABCB1). Pharm Res 2004: 21: 904.
17. Anglicheau D, Verstuyft C, Laurent-Puig P, et al,. Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients. J Am Soc Nephrol 2003: 14: 1889.
18. Foote CJ, Greer W, Kiberd BA, et al,. MDR1 C3435T polymorphisms correlate with cyclosporine levels in de novo renal recipients. Transplant Proc 2006: 38: 2847.
19. Picard N, Marquet P,. The influence of pharmacogenetics and cofactors on clinical outcomes in kidney transplantation. Expert Opin Drug Metab Toxicol 2011; 7: 731.
20. Sakaeda T,. MDR1 genotype-related pharmacokinetics: fact or fiction? Drug Metab Pharmacokinet 2005: 20: 391.
21. Kerb R,. Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett 2006: 234: 4.
22. Brenner SS, Klotz U,. P-glycoprotein function in the elderly. Eur J Clin Pharmacol 2004: 60: 97.
23. Owen A, Goldring C, Morgan P, Chadwick D, Park BK, Pirmohamed M,. Relationship between the C3435T and G2677T(A) polymorphisms in the ABCB1 gene and P-glycoprotein expression in human liver. Br J Clin Pharmacol 2005: 59: 365.
24. Illmer T, Schuler US, Thiede C, et al,. MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patients. Cancer Res 2002: 62: 4955.
25. Hitzl M, Schaeffeler E, Hocher B, et al,. Variable expression of P-glycoprotein in the human placenta and its association with mutations of the multidrug resistance 1 gene (MDR1, ABCB1). Pharmacogenetics 2004: 14: 309.
26. Lloberas N, Torras J, Alperovich G, et al,. Different renal toxicity profiles in the association of cyclosporine and tacrolimus with sirolimus in rats. Nephrol Dial Transplant 2008;.
27. Grinyo JM, Ekberg H, Mamelok RD, et al,. The pharmacokinetics of mycophenolate mofetil in renal transplant recipients receiving standard-dose or low-dose cyclosporine, low-dose tacrolimus or low-dose sirolimus: the Symphony pharmacokinetic substudy. Nephrol Dial Transplant 2009: 24: 2269.
28. Chiva-Blanch G, Gimenez-Bonafe P, Llaudo I, et al,. Different storing and processing conditions of human lymphocytes do not alter P-glycoprotein rhodamine 123 efflux. J Pharm Pharm Sci 2009: 12: 357.
29. Llaudõ I,. Impact of small molcules immunosuppressants on P-glycoprotein activity and T-cell function. J Pharm Pharm Sci, 2012.
30. del Moral RG, Andujar M, Ramirez C, et al,. Chronic cyclosporin A nephrotoxicity, P-glycoprotein overexpression, and relationships with intrarenal angiotensin II deposits. Am J Pathol 1997: 151: 1705.
31. Morales JM, Wramner L, Kreis H, et al,. Sirolimus does not exhibit nephrotoxicity compared to cyclosporine in renal transplant recipients. Am J Transplant 2002: 2: 436.
32. Wandel C, Kim RB, Kajiji S, Guengerich P, Wilkinson GR, Wood AJ,. P-glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory potencies. Cancer Res 1999: 59: 3944.
33. Yacyshyn BR, Bowen-Yacyshyn MB, Pilarski LM,. Inhibition by rapamycin of P-glycoprotein 170-mediated export from normal lymphocytes. Scand J Immunol 1996: 43: 449.
34. Achira M, Suzuki H, Ito K, Sugiyama Y,. Comparative studies to determine the selective inhibitors for P-glycoprotein and cytochrome P4503A4. AAPS Pharm Sci 1999: 1: E18.
35. Marzolini C, Paus E, Buclin T, Kim RB,. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther 2004: 75: 13.
36. Lopez-Montenegro Soria MA, Kanter Berga J, Beltran Catalan S, Milara Paya J, Pallardo Mateu LM, Jimenez Torres NV,. Genetic polymorphisms and individualized tacrolimus dosing. Transplant Proc 2010; 42: 3031.
37. Macphee IA, Fredericks S, Tai T, et al,. Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and P-glycoprotein correlate with dose requirement. Transplantation 2002: 74: 1486.
38. Roy JN, Barama A, Poirier C, Vinet B, Roger M,. Cyp3A4, Cyp3A5, and MDR-1 genetic influences on tacrolimus pharmacokinetics in renal transplant recipients. Pharmacogenet Genomics 2006: 16: 659.
39. Haufroid V, Mourad M, Van Kerckhove V, et al,. The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics 2004: 14: 147.
40. Mourad M, Mourad G, Wallemacq P, et al,. Sirolimus and tacrolimus trough concentrations and dose requirements after kidney transplantation in relation to CYP3A5 and MDR1 polymorphisms and steroids. Transplantation 2005: 80: 977.
41. Goto M, Masuda S, Saito H, et al,. C3435T polymorphism in the MDR1 gene affects the enterocyte expression level of CYP3A4 rather than Pgp in recipients of living-donor liver transplantation. Pharmacogenetics 2002: 12: 451.
42. Fellay J, Marzolini C, Meaden ER, et al,. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet 2002: 359: 30.
43. Hitzl M, Drescher S, van der Kuip H, et al,. The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells. Pharmacogenetics 2001: 11: 293.
44. Siegsmund M, Brinkmann U, Schaffeler E, et al,. Association of the P-glycoprotein transporter MDR1(C3435T) polymorphism with the susceptibility to renal epithelial tumors. J Am Soc Nephrol 2002: 13: 1847.
45. Schwab M, Eichelbaum M, Fromm MF,. Genetic polymorphisms of the human MDR1 drug transporter. Annu Rev Pharmacol Toxicol 2003: 43: 285.
46. Morita N, Yasumori T, Nakayama K,. Human MDR1 polymorphism: G2677T/A and C3435T have no effect on MDR1 transport activities. Biochem Pharmacol 2003: 65: 1843.
47. Oselin K, Gerloff T, Mrozikiewicz PM, Pahkla R, Roots I,. MDR1 polymorphisms G2677T in exon 21 and C3435T in exon 26 fail to affect rhodamine 123 efflux in peripheral blood lymphocytes. Fundam Clin Pharmacol 2003: 17: 463.
48. Hur EH, Lee JH, Lee MJ, et al,. C3435T polymorphism of the MDR1 gene is not associated with P-glycoprotein function of leukemic blasts and clinical outcome in patients with acute myeloid leukemia. Leuk Res 2008: 32: 1601.
49. Lourenco JJ, Maia RC, Scheiner MA, Vasconcelos FC, Moreira MA,. Genomic variation at the MDR1 promoter and P-glycoprotein expression and activity in AML patients. Leuk Res 2008: 32: 976.
50. Kim IW, Peng XH, Sauna ZE, et al,. The conserved tyrosine residues 401 and 1044 in ATP sites of human P-glycoprotein are critical for ATP binding and hydrolysis: evidence for a conserved subdomain, the A-loop in the ATP-binding cassette. Biochemistry 2006: 45: 7605.
51. Crowe A, Lemaire M,. In vitro and in situ absorption of SDZ-RAD using a human intestinal cell line (Caco-2) and a single pass perfusion model in rats: comparison with rapamycin. Pharm Res 1998: 15: 1666.
52. Lown KS, Mayo RR, Leichtman AB, et al,. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin Pharmacol Ther 1997: 62: 248.
53. Zheng H, Webber S, Zeevi A, et al,. Tacrolimus dosing in pediatric heart transplant patients is related to CYP3A5 and MDR1 gene polymorphisms. Am J Transplant 2003: 3: 477.
54. Hesselink DA, van Schaik RH, van der Heiden IP, et al,. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther 2003; 74: 245.
55. Kuypers DR, Naesens M, de Jonge H, Lerut E, Verbeke K, Vanrenterghem Y,. Tacrolimus dose requirements and CYP3A5 genotype and the development of calcineurin inhibitor-associated nephrotoxicity in renal allograft recipients. Ther Drug Monit 2010; 32: 394.
56. Wang P, Mao Y, Razo J, et al,. Using genetic and clinical factors to predict tacrolimus dose in renal transplant recipients. Pharmacogenomics 2010; 11: 1389.
57. Foote CJ, Greer W, Kiberd B, et al,. Polymorphisms of multidrug resistance gene (MDR1) and cyclosporine absorption in de novo renal transplant patients. Transplantation 2007: 83: 1380.
58. Chowbay B, Cumaraswamy S, Cheung YB, Zhou Q, Lee EJ,. Genetic polymorphisms in MDR1 and CYP3A4 genes in Asians and the influence of MDR1 haplotypes on cyclosporin disposition in heart transplant recipients. Pharmacogenetics 2003: 13: 89.
59. Yates CR, Zhang W, Song P, et al,. The effect of CYP3A5 and MDR1 polymorphic expression on cyclosporine oral disposition in renal transplant patients. J Clin Pharmacol 2003: 43: 555.